Literature DB >> 22156340

Size-dependent attenuation of TLR9 signaling by gold nanoparticles in macrophages.

Chiau-Yuang Tsai1, Shiou-Ling Lu, Chia-Wen Hu, Chen-Sheng Yeh, Gwo-Bin Lee, Huan-Yao Lei.   

Abstract

Gold nanoparticles (GNPs), which are generally thought to be bio-inert and non-cytotoxic, have become one of the most ideal nanomaterials for medical applications. Once engulfed by phagocytes, the immunological effects of GNPs are still of concern and require detailed investigation. Therefore, this study explored the immunological significance of GNPs on TLR-mediated innate immunity in murine macrophages. GNP causes specific inhibition of TLR9 (CpG oligodeoxynucleotides; CpG-ODNs) signal in macrophages. The impaired CpG-ODN-induced TNF-α production is GNP concentration- and size-dependent in murine Raw264.7 cells: a GNP of 4 nm in size is more potent than a GNP of 11, 19, 35, or 45 nm in size. Consistent with cytokine inhibition, the CpG-ODN-induced phosphorylation of NF-κB and JNK as well as NF-κB activation are suppressed by GNPs. GNPs accumulate in lysosomes after phagocytosis and also increase TLR9-associated lysosomal cathepsin expression and activities, but this is irrelevant to TLR9 inhibition by GNPs in our studies. In addition, GNPs affected TLR9 translocation in response to CpG-ODNs and to phagosomes. Further exploring how GNPs inhibited TLR9 function, we found that GNPs could bind to high-mobility group box-1 (which is involved in the regulation of TLR9 signaling) inside the lysosomes. The current studies demonstrate that size-dependent inhibition of TLR9 function by GNP may be attributed to its binding to high-mobility group box-1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22156340     DOI: 10.4049/jimmunol.1100344

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Low-dose gold nanoparticles exert subtle endocrine-modulating effects on the ovarian steroidogenic pathway ex vivo independent of oxidative stress.

Authors:  Jeremy K Larson; Michael J Carvan; Justin G Teeguarden; Gen Watanabe; Kazuyoshi Taya; Evan Krystofiak; Reinhold J Hutz
Journal:  Nanotoxicology       Date:  2014-12       Impact factor: 5.913

2.  Modifying Dendritic Cell Activation with Plasmonic Nano Vectors.

Authors:  Kieng Bao Vang; Ingrid Safina; Emilie Darrigues; Dmitry Nedosekin; Zeid A Nima; Waqar Majeed; Fumiya Watanabe; Ganesh Kannarpady; Rajshekhar A Kore; Daniel Casciano; Vladimir P Zharov; Robert J Griffin; Ruud P M Dings; Alexandru S Biris
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

Review 3.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors:  Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

4.  In vivo immune cell distribution of gold nanoparticles in naïve and tumor bearing mice.

Authors:  Joao Paulo Mattos Almeida; Adam Yuh Lin; Robert James Langsner; Phillip Eckels; Aaron Edward Foster; Rebekah Anna Drezek
Journal:  Small       Date:  2013-09-23       Impact factor: 13.281

Review 5.  Immunosuppressive and anti-inflammatory properties of engineered nanomaterials.

Authors:  A N Ilinskaya; M A Dobrovolskaia
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

Review 6.  Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications.

Authors:  Raziye Mohammadpour; Marina A Dobrovolskaia; Darwin L Cheney; Khaled F Greish; Hamidreza Ghandehari
Journal:  Adv Drug Deliv Rev       Date:  2019-07-08       Impact factor: 15.470

7.  Designing inorganic nanomaterials for vaccines and immunotherapies.

Authors:  Krystina L Hess; Igor L Medintz; Christopher M Jewell
Journal:  Nano Today       Date:  2019-05-29       Impact factor: 20.722

Review 8.  Immunotoxicological impact of engineered nanomaterial exposure: mechanisms of immune cell modulation.

Authors:  Xiaojia Wang; Shaun P Reece; Jared M Brown
Journal:  Toxicol Mech Methods       Date:  2013-01-17       Impact factor: 2.987

9.  Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.

Authors:  Kory L Alderson; Mitchell Luangrath; Megan M Elsenheimer; Stephen D Gillies; Fariba Navid; Alexander L Rakhmilevich; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2012-11-15       Impact factor: 6.968

10.  Materials design at the interface of nanoparticles and innate immunity.

Authors:  Gregory Lee Szeto; Erin B Lavik
Journal:  J Mater Chem B       Date:  2016-01-29       Impact factor: 6.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.